X-Chem and Astellas Collaborate
X-Chem, Inc., a privately held biotechnology company applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, announced the signing of a broad drug discovery collaboration with Astellas Pharma Inc. (Astellas). The collaboration will enable the discovery of novel lead compounds for complex drug targets of interest to Astellas from X-Chem’s growing collection of DNA-encoded DEX™ libraries containing over 120 billion compounds. This new partnership is X-Chem’s most expansive first-time alliance with a pharmaceutical company, and is aimed at tackling hard-to-drug targets across multiple therapeutic areas at Astellas.
“We are delighted to enter into a long-term relationship with a partner of the caliber of Astellas,” said Rick Wagner, Ph.D., Chief Executive Officer of X-Chem. “Our agreement is structured as a highly collaborative effort that has the potential to both be a leading source of new chemical entities into Astellas’ future portfolio and make a meaningful impact on the treatment of human diseases.”
Under the terms of this multi-year agreement, X-Chem will receive an up-front payment of $16M. X-Chem is eligible to receive research funding, as well as license and option fees as the drug discovery collaboration proceeds. Additionally, Astellas has the option to license compounds identified through this collaboration, and X-Chem will be entitled to pre-clinical, developmental, and commercial milestone payments on licensed compounds against each target. Milestone payments could amount to over $100M per target, in addition to royalties based on sales of future products.
“This is a transformational deal for X-Chem in terms of its scope and duration,” said O. Prem Das, Ph.D., Executive, Business Development at X-Chem. “It is customized to meet Astellas’ needs in generating novel lead structures against new and difficult targets. The transaction includes built-in mechanisms to expand the research scope, and enables increasing involvement and input of Astellas scientists in the DEX™-based discovery process over time.”
This article has been republished from materials provided by X-Chem. Note: material may have been edited for length and content. For further information, please contact the cited source.
Phenogenetic Map Created For Stem Cell Models Of Neurological DiseasesNews
Researchers at The Ohio State University Wexner Medical Center have performed the first meta-analysis of all induced pluripotent stem cell models for neurological and neurodegenerative diseases, and created an atlas of how cell characteristics are linked to their genotype.READ MORE
Diabetic Ketoacidosis Assay Collaboration Between Ortho Clinical Diagnostics and EKF DiagnosticsNews
EKF’s Beta-Hydroxybutyrate LiquiColor® Assay for detection of predominant ketone body now available on Ortho’s VITROS® 4600 Chemistry System and VITROS® 5600 Integrated System.READ MORE
Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until NowNews
A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.READ MORE